Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geriatric Syndromes Clear all
Not listed Phase 1Phase 2 Interventional

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

NCT01211457
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
sapacitabine and decitabine (Part 1 - completed), sapacitabine and venetoclax (Part 2 - recruiting)
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Jun 25, 2026, 2:59 PM EDT
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 1 Interventional

Voriconazole to Prevent Systemic Fungal Infections in Children

NCT00005912
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 2:59 PM EDT
Withdrawn Phase 3 Interventional

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02174094
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clobazam, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
1 Year to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)

NCT01048242
View directory record Official record
Conditions
Insomnia, Obstructive Sleep Apnea
Interventions
rozerem, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jun 25, 2026, 2:59 PM EDT
Terminated Not applicable Interventional Results available

Expanding Access to Comprehensive Geriatrics Care Via Telehealth

NCT05166603
View directory record Official record
Conditions
Geriatric Syndrome
Interventions
TeleGRACE
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
70 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Disparities in Late Life Depression and Metabolic Syndrome

NCT01428791
View directory record Official record
Conditions
Depressive Symptoms, Metabolic Syndrome X, Overweight, Obesity, Hypertension, Hyperglycemia, Dyslipidemias
Interventions
Generations older adult membership program, BRIGHTEN Heart Virtual Team intervention
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
60 Years to 110 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Not applicable Interventional Results available

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

NCT02121418
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Bozeman, Montana • Kennewick, Washington • Kirkland, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults

NCT00581074
View directory record Official record
Conditions
Obesity
Interventions
diet (grapefruit or grapefruit juice)
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

NCT01379183
View directory record Official record
Conditions
Healthy
Interventions
Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

Ghrelin Plus Strength Training in Frail Elderly Study

NCT01898611
View directory record Official record
Conditions
Frailty Syndrome
Interventions
Ghrelin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
70 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

NCT05630066
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Alogabat
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

NCT00590187
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sapacitabine, Arm A, Sapacitabine, Arm B, Sapacitabine, Arm C, Sapacitabine, Arm D, sapacitabine, Arm E, sapacitabine, Arm F, Sapacitabine, Arm G, Sapacitabine, Arm H, Sapacitabine, Arm I
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 25, 2026, 2:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Preoperative Cognitive Screening in Older Spinal Surgical Patients

NCT02922634
View directory record Official record
Conditions
Cognitive Impairment, Frail Elderly Syndrome
Interventions
Mini Cog
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
70 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jun 25, 2026, 2:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Selumetinib granule formulation, Selumetinib capsule formulation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

NCT00607997
View directory record Official record
Conditions
Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
vosaroxin
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jun 25, 2026, 2:59 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly

NCT01145703
View directory record Official record
Conditions
Vitamin D Deficiency, Metabolic Syndrome
Interventions
RDA Vitamin D3 only, Vitamin D2/3 Repletion only, Vitamin D2/3 Repletion + AEX, Vitamin D2/3 Repletion + RT
Dietary Supplement · Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
40 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Jun 25, 2026, 2:59 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Metabolic Syndrome in an Elderly Population is More Linked to Insulin Resistance Than to Obesity

NCT00873964
View directory record Official record
Conditions
Metabolic Syndrome in the Elderly
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
60 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Jun 25, 2026, 2:59 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cellular Senescence and COVID-19 Long-Hauler Syndrome

NCT04903132
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women

NCT00912210
View directory record Official record
Conditions
Bone and Body Composition, Obesity, Metabolic Syndrome, Physical Function, Quality of Life
Interventions
Whey protein isolate, Maltodextrin powder supplement
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Jun 25, 2026, 2:59 PM EDT
Not listed Not applicable Interventional Results available

Electroencephalography Guidance of Anesthesia

NCT02241655
View directory record Official record
Conditions
Delirium
Interventions
a pragmatic EEG-guided anesthetic protocol
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Phase 1 Interventional

Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

NCT00892190
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
dasatinib (SPRYCEL), all trans retinoic acid (VESANOID)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Jun 25, 2026, 2:59 PM EDT
Completed Not applicable Interventional

Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients

NCT03636412
View directory record Official record
Conditions
Transplant-Related Disorder, Frail Elderly Syndrome, Sarcopenia, Lung Graft Dysfunction, Mobility Limitation
Interventions
Ambulation
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 25, 2026, 2:59 PM EDT